Research Summary

CLINICAL INTERESTS:
Cardio-Oncology, Cardio-Immunology

RESEARCH INTERESTS:
I am a cardiologist and myocyte biologist. My clinical focus is cardio-oncology and cardio-immunology. My clinical interests overlap with my laboratory focus, where we are investigating the mechanistic underpinnings of cardiovascular sequelae of novel targeted and immune-based cancer therapies.

Since 2016, a major focus of my clinical and research program has been the interaction between the cardiovascular and immune systems. Our group initially described a novel clinical syndrome of fulminant myocarditis that arises from (ICI) immune checkpoint inhibitors (Johnson et al, NEJM, 2016). We further defined the clinical characteristics of ICI-associated myocarditis (Moslehi et al, Lancet, 2018) and showed that cardiovascular sequelae of ICI include pericarditis, vasculitis and arrhythmias (Salem et al, Lancet Oncology, 2018). My laboratory has generated mouse models that recapitulate these novel immune-based clinical syndromes which have provided insights into new diagnostic and treatment strategies for these complications (Bonaca et al, Circulation, 2019; Salem et al, NEJM, 2019; Wei et al, Cancer Discovery, 2021). My interest in this space has recently expanded to other inflammatory cardiomyopathies, including giant cell myocarditis, acute cellular rejection (ACR) following cardiac transplantation, and other forms of myocarditis. Our group is further investigating the how the immune system can be harnessed to treat heart disease.

Research Funding

  • May 1, 2021 - April 30, 2026 - Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated Myocarditis , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01HL156021
  • May 1, 2021 - April 30, 2026 - Long-Term Cardiovascular Sequelae of Cancer Immunotherapies , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01HL155990
  • August 1, 2019 - May 31, 2024 - Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01HL141466
  • September 15, 2018 - August 31, 2019 - Novel mechanisms and predictors of VEGF receptor inhibitor-associated hypertension , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R56HL141466

Education

  • Johns Hopkins University, BA, 1996, Biology
  • University of Connecticut School of Medicine, MD, 2001, Medicine

Honors & Awards

  • Inaugural Holder of the William Grossman Distinguished Professorship in Cardiology, UCSF, 2021
  • Elected Member, American Society of Clinical Investigation (ASCI), 2020
  • Alumni Achievement Award, Stanley J. Sarnoff Cardiovascular Research Foundation, 2016
  • Biomedical Science Impact Award, Vanderbilt University, 2016
  • Thomas Smith Award in Heart Failure Research, Brigham and Women's Hospital, Harvard Medical School, 2009

Selected Publications

  1. Szczepaniak P, Siedlinski M, Hodorowicz-Zaniewska D, Nosalski R, Mikolajczyk TP, Dobosz AM, Dikalova A, Dikalov S, Streb J, Gara K, Basta P, Krolczyk J, Sulicka-Grodzicka J, Jozefczuk E, Dziewulska A, Saju B, Laksa I, Chen W, Dormer J, Tomaszewski M, Maffia P, Czesnikiewicz-Guzik M, Crea F, Dobrzyn A, Moslehi J, Grodzicki T, Harrison DG, Guzik TJ. Breast cancer chemotherapy induces vascular dysfunction and hypertension through NOX4 dependent mechanism. J Clin Invest. 2022 May 26.  View on PubMed
  2. Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek SS, Asnani A, Tamura Y, Aras M, Cautela J, Thuny F, Gilstrap L, Arangalage D, Ewer S, Huang S, Deswal A, Palaskas NL, Finke D, Lehmann LH, Ederhy S, Moslehi J, Salem JE, International ICI-Myocarditis Registry. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. Arch Cardiovasc Dis. 2022 Apr 27.  View on PubMed
  3. Karlstaedt A, Moslehi J, de Boer RA. Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer. Nat Rev Cardiol. 2022 Apr 19.  View on PubMed
  4. Nguyen LS, Bretagne M, Arrondeau J, Zahr N, Ederhy S, Abbar B, Pinna B, Allenbach Y, Mira JP, Moslehi J, Rosenzwajg M, Salem JE. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J Immunother Cancer. 2022 Apr; 10(4).  View on PubMed
  5. Ammirati E, Bizzi E, Veronese G, Groh M, Van de Heyning CM, Lehtonen J, Pineton de Chambrun M, Cereda A, Picchi C, Trotta L, Moslehi JJ, Brucato A. Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis. Front Med (Lausanne). 2022; 9:838564.  View on PubMed
  6. Rini BI, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, Motzer RJ, Atkins MB, Haanen J, Mariani M, Wang J, Hariharan S, Larkin J. Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. J Clin Oncol. 2022 Mar 03; JCO2101806.  View on PubMed
  7. Wilcox NS, Rotz SJ, Mullen M, Song EJ, Ky Hamilton B, Moslehi J, Armenian SH, Wu JC, Rhee JW, Ky B. Sex-Specific Cardiovascular Risks of Cancer and Its Therapies. Circ Res. 2022 02 18; 130(4):632-651.  View on PubMed
  8. Ederhy S, Devos P, Pinna B, Funck-Brentano E, Abbar B, Fenioux C, Cohen AA, Moslehi J, Bretagne M, Allenbach Y, Kharroubi D, Salem JE. 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis. Arch Cardiovasc Dis. 2022 Feb; 115(2):114-116.  View on PubMed
  9. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022 Apr; 19(4):254-267.  View on PubMed
  10. Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L. Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol. 2022 04; 19(4):269-280.  View on PubMed
  11. Nguyen LS, Cooper LT, Kerneis M, Funck-Brentano C, Silvain J, Brechot N, Hekimian G, Ammirati E, Ben M'Barek B, Redheuil A, Gandjbakhch E, Bihan K, Lebrun-Vignes B, Ederhy S, Dolladille C, Moslehi JJ, Salem JE. Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. Nat Commun. 2022 01 10; 13(1):25.  View on PubMed
  12. Zaha VG, Hayek SS, Alexander KM, Beckie TM, Hundley WG, Kondapalli L, Ky B, Leger KJ, Meijers WC, Moslehi JJ, Shah SH. Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association. Circulation. 2021 12 21; 144(25):e551-e563.  View on PubMed
  13. Mohamed TMA, Moslehi J, Satin J. Editorial: Recent Advances in Cardiotoxicity Testing. Front Pharmacol. 2021; 12:798189.  View on PubMed
  14. Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y, Alexandre J, Rassaf T, Müller OJ, Aras M, Asnani AH, Deswal A, Laufer-Perl M, Thuny F, Kerneis M, Hayek SS, Ederhy S, Salem JE, Moslehi JJ. Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review. JAMA Cardiol. 2021 11 01; 6(11):1329-1337.  View on PubMed
  15. Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, Tamura Y, Aras M, Cautela J, Thuny F, Gilstrap L, Arangalage D, Ewer S, Huang S, Deswal A, Palaskas NL, Finke D, Lehman L, Ederhy S, Moslehi J, Salem JE, International ICI-Myocarditis Registry†. Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. Circulation. 2021 11 02; 144(18):1521-1523.  View on PubMed
  16. Salem JE, Nguyen LS, Moslehi JJ, Ederhy S, Lebrun-Vignes B, Roden DM, Funck-Brentano C, Gougis P. Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. Eur Heart J. 2021 10 07; 42(38):3915-3928.  View on PubMed
  17. Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ, Salem JE, Schaefer N, Nicod-Lalonde M, Costes J, Perreau M, Michielin O, Peters S, Prior JO, Obeid M. 68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. J Immunother Cancer. 2021 10; 9(10).  View on PubMed
  18. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2021 Sep 30.  View on PubMed
  19. Choudhary A, Brinkley DM, Besharati S, Meijers WC, Atkinson JB, Amancherla K, Zhu Q, Huang S, Nguyen LS, Salem JE, Ammirati E, Lindenfeld J, Anders RA, Moslehi J. PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation. Circ Heart Fail. 2021 10; 14(10):e008563.  View on PubMed
  20. Hu JR, Patel A, Huang S, Su YR, Dahlman KB, Tomasek K, Zhang Y, O'Neil RT, O'Neal JF, Turker I, Johnson DB, Salem JE, Moslehi JJ, Oluwole O. High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy. Clin Hematol Int. 2021 Sep; 3(3):96-102.  View on PubMed

Go to UCSF Profiles, powered by CTSI